Aprea Therapeutics (APRE) stock

Worth $6.3MShares as of Nov 4

$0.45

-11.06%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score APRE. It is too small, priced too low, and too thinly traded for a fair Quality Score.

Healthcare · Biotech

NextQ4 2026“…to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026…”Trial data · SEC filing · Aug 12

Follow APRE's trial news. Pro members can get an alert when Aprea Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when APRE files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for APRE, and how long its cash lasts

Next step the company has named

Q4 2026“Aprea expects to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026.”Trial data · SEC filing · Aug 12

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: ACESOT-1051 · Advanced Solid Tumor · Phase 1
Its trial: ACESOT-1051Phase 1 · Recruiting · 90 people · main data estimated Jun 2027 · NCT06260514

For Pro members: 2 more milestones and 39 filings.

Cash runway

The company says its cash lasts into the first quarter of 2028 (8-K, Nov 4).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Jan 26, 2024)
At-the-market share sales program (424B5, filed Nov 8, 2024)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CEO Oren Gilad bought 28,100 shares on Jan 30. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

Get an alert when Oren Gilad buys or sells

For Pro members: every trade, and Oren Gilad’s 17 filings and quotes.

Get an alert when APRE files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

APRE's latest filings

Quarterly report10-Q, filed Nov 4
Aprea Therapeutics Announces Third Quarter 2026 Financial Results Updated interim Phase 1 data for oral WEE1 inhibitor8-K, filed Nov 4
8 insider filingsForm 4, filed Jun 17

29 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why APRE isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. APRE is worth about $6.3M, trades at $0.45, and about 152,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.